#6 - Caribou Biosciences (NASDAQ:CRBU)
Finding a cure for cancer remains elusive despite the progress made. I’ve included Caribou Biosciences, Inc. (NASDAQ: CRBU) on this list because they are laser-focused on finding cancer treatments. Caribou focuses on chimeric antigen receptor T cell therapy (CAR-T).
In CAR-T cell therapy, engineered molecules called chimeric antigen receptors (CARs) identify and destory antigens found in lymphoma cells. The company has candidates to treat blood cancer in stage 1 trials. And the company is also working on getting candidates to treat solid tumors into clinical trials.
The company is also partnering with AbbVie Inc. (NYSE: ABBV) to develop additional CAR-T cell therapies that can be enhanced with CRISPR gene editing technology.
However, as an illustration of how volatile these stocks can be, Caribou posted positive results in its Stage 1 trial but CRBU stock still dropped. Still, Caribou receives a Buy rating from the analysts surveyed by MarketBeat with a price target that is 265% above its current level.
About Caribou Biosciences
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Read More - Current Price
- $1.80
- Consensus Rating
- Buy
- Ratings Breakdown
- 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $10.20 (466.7% Upside)
